Bortezomib-Induced Painful Peripheral Neuropathy: An Electrophysiological, Behavioral, Morphological and Mechanistic Study in the Mouse

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Carozzi, Valentina A ^a   Renn, Cynthia L ^b   Bardini, Michela ^a   Fazio, Grazia ^a   Chiorazzi, Alessia ^a   Meregalli, Cristina ^a   Oggioni, Norberto ^a   Shanks, Kathleen ^b   Quartu, Marina ^c   Serra, Maria Pina ^c   Sala, Barbara ^a   Cavaletti, Guido ^a   Dorsey, Susan G ^b  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b UNIVERSITY OF MARYLAND SCHOOL OF NURSING   (United States)

^c UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; TRANSCRIPTION FACTOR 3;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DELTA NERVE FIBER; FEMALE; IMMUNE RESPONSE; LEUKOCYTE COUNT; MOUSE; NERVE FIBER C; NEUROPATHIC PAIN; NONHUMAN; PATHOPHYSIOLOGY; PERIPHERAL NERVE; PERIPHERAL NERVOUS SYSTEM; PERIPHERAL NEUROPATHY; PROTEIN EXPRESSION; SPINAL CORD NERVE CELL; SPINAL GANGLION; WEIGHT CHANGE;

ACTIVATING TRANSCRIPTION FACTOR 3; ANIMALS; BORONIC ACIDS; ELECTROPHYSIOLOGY; FEMALE; MICE; MICE, INBRED BALB C; PERIPHERAL NERVOUS SYSTEM DISEASES; PYRAZINES;

EID: 84884191612     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0072995     Document Type: Article

References (77)

1. Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, et al. (1999) Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 59: 2615-2622. PubMed: 10363983.
2. Curran MP, McKeage K, (2009) Bortezomib: a review of its use in patients with multiple myeloma. Drugs 69: 859-888. doi:10.2165/00003495-200969070-00006. PubMed: 19441872.
3. Mahindra A, Laubach J, Raje N, Munshi N, Richardson PG, et al. (2012) Latest advances and current challenges in the treatment of multiple myeloma. Nat Rev Clin Oncol 9: 135-143. doi:10.1038/nrclinonc.2012.15. PubMed: 22349016.
4. Tobinai K, (2007) Proteasome inhibitor, bortezomib, for myeloma and lymphoma. Int J Clin Oncol 12: 318-326. doi:10.1007/s10147-007-0695-5. PubMed: 17929113.
5. Kennedy B, Gargoum F, Bystricky B, Curran DR, O'Connor TM, (2010) Novel agents in the management of lung cancer. Curr Med Chem 17: 4291-4325. doi:10.2174/092986710793361289. PubMed: 20939812.
6. Bonvini P, Zorzi E, Basso G, Rosolen A, (2007) Bortezomib-mediated 26S proteasome inhibition causes cell-cycle arrest and induces apoptosis in CD-30 anaplastic large cell lymphoma. Leukemia 21: 838-842. PubMed: 17268529.
7. Hideshima T, Chauhan D, Richardson P, Mitsiades C, Mitsiades N, et al. (2002) NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem 277: 16639-16647. doi:10.1074/jbc.M200360200. PubMed: 11872748.
8. Lenz HJ, (2003) Clinical update: proteasome inhibitors in solid tumours. Cancer Treat Rev 29: 41-48. doi:10.1016/S0305-7372(03)00082-3. PubMed: 12738242.
9. Grisold W, Cavaletti G, Windebank AJ, (2012) Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention. NeuroOncol 14: 45-54. PubMed: 23095830.
10. Lanzani F, Mattavelli L, Frigeni B, Rossini F, Cammarota S, et al. (2008) Role of a pre-existing neuropathy on the course of bortezomib-induced peripheral neurotoxicity. J Peripher Nerv Syst 13: 267-274. doi:10.1111/j.1529-8027.2008.00192.x. PubMed: 19192066.
11. Chaudhry V, Cornblath DR, Polydefkis M, Ferguson A, Borrello I, (2008) Characteristics of bortezomib- and thalidomide-inducedperipheral neuropathy. J Peripher Nerv Syst 13: 275-282. doi:10.1111/j.1529-8027.2008.00193.x. PubMed: 19192067.
12. Argyriou AA, Iconomou, Kalofonos HP, (2008) Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. Blood 112: 1593-1599. doi:10.1182/blood-2008-04-149385. PubMed: 18574024.
13. Ravaglia S, Corso A, Piccolo G, Lozza A, Alfonsi E, et al. (2008) Immune-mediated neuropathies in myeloma patients treated with bortezomib. Clin Neurophysiol 119: 2507-2512. doi:10.1016/j.clinph.2008.08.007. PubMed: 18829381.
14. Giannoccaro MP, Donadio V, GomisPèrez C, Borsini W, Di Stasi V, et al. (2011) Somatic and autonomic small fiber neuropathy induced by bortezomib therapy: an immunofluorescence study. NeurolSci32:361-363.
15. McMahon G, Wall PD, (1984) Receptive fields of rat lamina 1 projection cells move to incorporate a nearby region of injury. Pain 19: 235-248. doi:10.1016/0304-3959(84)90002-2. PubMed: 6089072.
16. Cervero J, Laird MA, (1996) Mechanisms of touch-evoked pain (allodynia): a new model. Pain 68: 13-23. doi:10.1016/S0304-3959(96)03165-X.
17. Guilbaud JM, Benoist F, Jazat N, Gautron M, (1990) Neuronal responsiveness in the ventrobasal thalamic complex of rats with an experimental peripheral mononeuropathy. J Neurophysiol 64: 1537-1554. PubMed: 2283540.
18. Ossipov D, Bian TP, Malan J, Lai B, Porreca F, (1999) Lack of involvement of capsaicin-sensitive primary afferent nerve-ligation injury induced tactile allodynia in rats. Pain 79: 127-133. doi:10.1016/S0304-3959(98)00187-0.
19. Cavaletti G, Gilardini A, Canta A, Rigamonti L, Rodriguez-Menendez V, et al. (2007a) Bortezomib-induced peripheral neurotoxicity: a neurophysiological and pathological study in the rat. Exp Neurol 204: 317-325. doi:10.1016/j.expneurol.2006.11.010.
20. Meregalli C, Canta A, Carozzi VA, Chiorazzi A, Oggioni N, et al. (2010) Bortezomib-induced painful neuropathy in rats: a behavioral, neurophysiological and pathological study in rats. Eur J Pain 4: 343-350.
21. Carozzi VA, Canta A, Oggioni N, Sala B, Chiorazzi A, et al. (2010a) Neurophysiological and neuropathological characterization of new murine models of chemotherapy-induced chronic peripheral neuropathies. Exp Neurol 226: 301-309. doi:10.1016/j.expneurol.2010.09.004.
22. Bruna J, Udina E, Alé A, Vilches JJ, Vynckier A, et al. (2010) Neurophysiological, histological and immunohistochemical characterization of bortezomib-induced neuropathy in mice. Exp Neurol 23: 599-608.
23. Nakano A, Abe M, Oda A, Amou H, Hiasa M, et al. (2011) Delayed treatment with vitamin C and N-acetyl-L-cysteine protects Schwann cells without compromising the anti-myeloma activity of bortezomib. Int J Hematol 93: 727-735. doi:10.1007/s12185-011-0850-7. PubMed: 21526377.
24. Broyl A, Corthals SL, Jongen JL, van der Holt B, Kuiper R, et al. (2010) Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial. Lancet Oncol 11: 1057-1065. doi:10.1016/S1470-2045(10)70206-0.
25. Carozzi VA, Chiorazzi A, Canta A, Lapidus RG, Slusher BS, et al. (2010b) Glutamate carboxypeptidase inhibition reduces the severity of chemotherapy-induced peripheral neurotoxicity in rat. Neurotox Res 17: 380-391. doi:10.1007/s12640-009-9114-1.
26. Ledeboer A, Jekich BM, Sloane EM, Mahoney JH, Langer SJ, et al. (2007) Intrathecal interleukin-10 gene therapy attenuates paclitaxel-induced mechanical allodynia and proinflammatory cytokine expression in dorsal root ganglia in rats. Brain Behav Immun 21: 686-698. doi:10.1016/j.bbi.2006.10.012.
27. Muthuraman A, Singh N, Jaggi AS, (2011) Protective effect of Acorus calamus L. in rat model of vincristine induced painful neuropathy: an evidence of anti-inflammatory and anti-oxidative activity. Food Chem Toxicol 49: 2557-2563. doi:10.1016/j.fct.2011.06.069.
28. Jaggi AS, Singh N, (2012) Mechanisms in cancer-chemotherapeutic drugs-induced peripheral neuropathy. Toxicology 291: 1-9. doi:10.1016/j.tox.2011.10.019. PubMed: 22079234.
29. Li J, Zhang H, Huang W, Qian H, Li Y, (2012) TNF-a inhibitors with anti-oxidative stress activity from natural products. Curr Top Med Chem 12: 1408-1421. doi:10.2174/156802612801784434.
30. Jeter A, Kang Y, (2012) Immune modulation therapy in the management of bortezomib-induced peripheral neuropathy. ExpHematolOncol 1: 1-20.
31. Zimmermann M, (1983) Ethical guidelines for investigations of experimental pain in conscious animals. Pain 16: 109-110. doi:10.1016/0304-3959(83)90201-4.
32. Motta EM, Calixto JB, Rae GA, (2006) Mechanical hyperalgesia induced by endothelin-1 in rats is mediated via phospholipase C, protein kinase C, and MAP kinases. Exp Biol Med (Maywood). 231: 1141-1145.
33. Renn CL, Carozzi VA, Rhee P, Gallop D, Dorsey SG, et al. (2011a) Multimodal assessment of painful peripheral neuropathy induced by chronic oxaliplatin-based chemotherapy in mice. Mol Pain 26: 7-29.
34. Ueda H, Matsumoto M, (2008) Novel sensory fiber-specific nociception test with the Neurometer. Nihon YakurigakuZasshi 131: 367-371. doi:10.1254/fpj.131.367.
35. Matsumoto M, Inoue M, Hald A, Yamaguchi A, Ueda H, (2006) Characterization of three different sensory fibers by use of neonatal capsaicin treatment, spinal antagonism and a novel electrical stimulation-induced paw flexion test. Mol Pain 2: 16. doi:10.1186/1744-8069-2-16.
36. Cavaletti G, Tredici G, Braga M, Tazzari S, (1995) Experimental peripheral neuropathy induced in adult rats by repeated intraperitoneal administration of taxol. Exp Neurol 133: 64-72. doi:10.1006/exnr.1995.1008.
37. Marmiroli P, Rodriguez-Menendez V, Rigamonti L, Tonoli E, Rigolio R, et al. (2009) Neuropathological changes in the peripheral nervous system and spinal cord in a transgenic mouse model of Niemann-Pick disease type A. Clin Neuropathol 28: 263-274. PubMed: 19642505.
38. Kortum M, Einsele H, (2011) Results of the first bortezomib-based induction therapy in the treatment of multiple myeloma. ExpOpin Pharm 12: 1661-1663.
39. Cavaletti G, Nobile-Orazio E, (2007b) Bortezomib-induced peripheral neurotoxicity: still far from a painless gain. Haematologica 92: 1308-1310. doi:10.3324/haematol.11752. PubMed: 18024368.
40. Freimann H, Calderoni A, Cornu P, Olie R, (2007) Daily practice of use of bortezomib in relapsed/refractory multiple myeloma. Safety/efficacy results of a compassionate use program in Switzerland. Swiss Med Wkly 137: 317-322. PubMed: 17629810.
41. Cavaletti G, Jakubowiak AJ, (2010) Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies. Leik Lymphoma 51: 1178-1187. doi:10.3109/10428194.2010.483303.
42. Cata JP, Weng HR, Burton AW, Villareal H, Giralt S, et al. (2007) Quantitative sensory findings in patients with bortezomib-induced pain. J Pain 8: 296-306. doi:10.1016/j.jpain.2006.09.014.
43. Schaumberg H, Zotova E, Rain CS, Tar M, Arezzo J, (2010) The rat caudal nerves: a model of experimental neuropathies. J PeriphNervSyst 15: 128-139.
44. Badros A, Goloubeva O, Dalal JS, Can I, Thompson J, et al. (2007) Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature. Cancer 110: 1042-1049. doi:10.1002/cncr.22921. PubMed: 17654660.
45. Koga K, Furue H, Rashid H, Takaki A, Katafuchi T, et al. (2005) Selective activation of primary afferent fibers evaluated by sine-wave electrical stimulation. Mol Pain 1: 13. doi:10.1186/1744-8069-1-13.
46. Matsumoto M, Xie W, Ma L, Ueda H, (2008) Pharmacological switch in Aβ-fiber stimulation-induced spinal transmission in mice with partial sciatic nerve injury. Mol Pain 4: 25. doi:10.1186/1744-8069-4-25. PubMed: 18620588.
47. Ma L, Nagai J, Sekinl Y, Goto Y, Nakahira S, et al. (2012) Single application of A2 NTX, a botulinum toxin A2 subunit, prevents chronic pain over long periods in both diabetic and spinal cord injury-induced neuropathic pain models. J Pharmacol Sci 119: 282-286. doi:10.1254/jphs.12080SC.
48. Authier N, Gillet JP, Fialip J, Eschalier A, Coudore F, (2003) A new animal model of vincristine-induced nociceptive peripheral neuropathy. Neurtoxicol24:797-805.
49. Joh T, Sigematu K, Yasui JI, Takasaki Y, Tawara M, et al. (2009) Dorsal Column Degeneration after Bortezomib Therapy in a Patient with Multiple Myeloma. Case Rep Oncol 14:184-188.
50. Back SK, Kim JS, Hong SK, Na HS, (2003) Ascending pathways for mechanical allodynia in a rat model of neuropathic pain. Neuroreport 23: 1623-1626.
51. Saadé NE, Baliki M, El-Khoury C, Hawwa N, Atweh SF, et al. (2002) The role of the dorsal columns in neuropathic behavior: evidence for plasticity and non-specificity. Neuroscience 115: 403-413. PubMed: 12421606.
52. Obata K, Yamanaka H, Dai Y, Mizushima T, Fukuoka T, et al. (2004) Contribution of degeneration of motor and sensory fibers to pain behavior and the changes in neurotrophic factors in rat dorsal root ganglion. Exp Neurol 188: 149-160. PubMed: 15191811.
53. Tsujino H, Kondo E, Fukuoka T, Dai Y, Tokunaga A, et al. (2000) Activating transcription factor 3 (ATF3) induction by axotomy in sensory and motoneurons: A novel neuronal marker of nerve injury. Mol Cell Neurosci 15: 170-182. PubMed: 10673325.
54. Lindå H, Sköld MK, Ochsmann T, (2011) Activating transcription factor 3, a useful marker for regenerative response after nerve root injury. Front Neurol 2: 30. PubMed: 21629765.
55. Hunt D, Raivich G, Anderson PN, (2012) Activating transcription factor 3 and the nervous system. Front. J Mol Neurosci 5: 7.
56. Khasabova IA, Khasabov S, Paz J, Harding-Rose C, Simone DA, et al. (2012) Cannabinoid type-1 receptor reduces pain and neurotoxicity produced by Chemotherapy. J Neurosci 32: 7091-7101. PubMed: 22593077.
57. Jimenez-Andrade JM, Peters CM, Mejia NA, Ghilardi JR, Kuskowski MA, et al. (2006) Sensory neurons and their supporting cells located in the trigeminal, thoracic and lumbar ganglia differentially express markers of injury following intravenous administration of paclitaxel in the rat. Neurosci Lett 405: 62-67. PubMed: 16854522.
58. Mitchell K, Bates BD, Keller JM, Lopez M, Scholl L, et al. (2010) Ablation of rat TRPV1-expressing A delta/C-fibers with resiniferatoxin: analysis of withdrawal behaviors, recovery of function and molecular correlates. Mol Pain 17: 694.
59. Jazirehi AR, Economou JS, (2012) Proteasome inhibition blocks NF-κB and ERK1/2 pathways, restores antigen expression, and sensitizes resistant human melanoma to TCR-engineered CTLs. Mol Cancer Ther 11: 1332-1341. PubMed: 22532603.
60. Lindwall C, Dahlin L, Lundborg G, Kanje M, (2004) Inhibition of c-Jun phosphorylation reduces axonal outgrowth of adult rat nodose ganglia and dorsal root ganglia sensory neurons. Mol Cell Neurosci 27: 267-279. PubMed: 15519242.
61. Tsuzuki K, Kondo E, Fukuoka T, Yi D, Tsujino H, et al. (2001) Differential regulation of P2X(3) mRNA expression by peripheral nerve injury in intact and injured neurons in the rat sensory ganglia. Pain 91: 351-360. PubMed: 11275393.
62. Seijffers R, Mills CD, Woolf CJ, (2007) ATF3 increases the intrinsic growth state of DRG neurons to enhance peripheral nerve regeneration. J Neurosci 27: 7911-7920. PubMed: 17652582.
63. Woolf CJ, (1983) Evidence for a central component of post-injury pain hypersensitivity. Nature 306: 686-688. PubMed: 6656869.
64. Laird JM, Bennett GJ, (1993) An electrophysiological study of dorsal horn neurons in the spinal cord of rats with an experimental peripheral neuropathy. J Neurophysiol 69: 2072-2085. PubMed: 8394412.
65. Palecek J, Dougherty PM, Kim SH, Lekan HA, Carlton SM, et al. (1993) Responses of spinothalamic tract neurons to mechanical and thermal stimuli in an experimental model of peripheral neuropathy in primates. J Neurophysiol 68: 1951-1966.
66. Sotgiu ML, Biella G, ((1997)) Role of input from saphenous afferents in altered spinal processing of noxious signal that follows sciatic nerve constriction in rats. Neurosci Lett 223: 101-104.
67. Groth R, Aanonsen L, ((2002)) Spinal brain-derived neurotrophic factor (BDNF) produces hyperalgesia in normal mice while antisense, directed against either BDNF or trkB, prevent infl{ligature}ammation-induced hyperalgesia. Pain 100: 171-181.
68. Lu VB, Ballanyi K, Colmers WF, Smith PA, ((2007)) Neuron type-specific effects of brain-derived neurotrophic factor in rat superficial dorsal horn and their relevance to 'central sensitization'. J Physiol 584: 543-563.
69. Shen H, Chung JM, Chung K, ((1999)) Expression of neurotrophin mRNAs in the dorsal root ganglion after spinal Nerve injury. Res Mol Brain Res 64: 186-192.
70. Lu VB, Biggs JE, Stebbing MJ, Balasubramanyan S, Todd KG, et al.((2009)) Brain-derived neurotrophic factor drives the changes in excitatory synaptic transmission in the rat superficial dorsal horn that follow sciatic nerve injury. J Physiol 587: 1013-1032. PubMed: 19124536.
71. Pertovaara A, Wei H, Kalmari J, Ruotsalainen M, ((2001)) Pain behavior and response properties of spinal dorsal horn neurons following experimental diabetic neuropathy in the rat: modulation by nitecapone, a COMT inhibitor with antioxidant properties. Exp Neurol 167: 425-434. PubMed: 11161631.
72. Weng H-R, Cordella JV, Dougherty PM, ((2003)) Changes in sensory processing in the spinal dorsal horn accompany vincristine-induced hyperalgesia and allodynia. Pain 103: 131-138. PubMed: 12749967.
73. Cata JP, Weng HR, Dougherty PM, ((2008a)) Behavioral and electrophysiological studies in rats with cisplatin-induced chemoneuropathy. Brain Res 1230: 91-98. PubMed: 18657527.
74. Renn CL, Leitch CC, Lessans S, Rhee P, McGuire WC, et al.((2011b)) Brain-derived neurotrophic factor modulates antiretroviral-induced mechanical allodynia in the mouse. J Neurosci Res 89: 1551-1565. PubMed: 21647939.
75. Saifee TA, Elliott KJ, Rabin N, Yong KL, D'Sa S, et al.((2010)) Bortezomib-induced inflammatory neuropathy. J Peripher Nerv Syst 15: 366-368. PubMed: 21199108.
76. Mangiacavalli S, Corso A, De Amici M, Varettoni M, Alfonsi E, et al.((2010)) Emergent T-helper 2 profile with high interleukin-6 levels correlates with the appearance of bortezomib-induced neuropathic pain. Br J Haematol 149: 916-918. PubMed: 20201942.
77. Glineur S, Antoine-Moussiaux N, Michaux C, Desmecht D, ((2011)) Immune depression of the SJL/J mouse, a radioresistant and immunologically atypical inbred strain. Immunobiology 216: 213-217. PubMed: 20965099.